Results 81 to 90 of about 3,505 (170)

Voiding dysfunction - A review

Journal of Indian Association of Pediatric Surgeons, 2005
In a child who is toilet trained the sudden onset of daytime wetting with frequency or urgency is alarming to the parents. Initially this subject was subdivided into a number of descriptive clinical conditions which led to a lot of confusion in ...
Sripathi V
doaj  

Impact of the suspension of neurogenic detrusor overactivity treatment with botulinum toxin due to the COVID-19 pandemic. [PDF]

Urologia, 2023
Freitas Ferreira E, Silva R, Ferreira A, Paz Carvalho M, Vale P, Faria F.   +5 more
europepmc   +1 more source

Efficacy, according to urodynamics, of OnabotulinumtoxinA compared with antimuscarinic drugs, for neurogenic detrusor overactivity: a systematic review and network meta-analysis. [PDF]

Sci Rep, 2022
Xu R, Yang TX, Fang KW, Wang G, Li P.
europepmc   +1 more source

BoNT/A1 Secondary Failure for the Treatment of Neurogenic Detrusor Overactivity: An Ex Vivo Functional Study. [PDF]

Toxins (Basel), 2022
Maignel J, Martin V, Assaly R, Vogt ML, Retailleau K, Hornby F, Laugerotte A, Lezmi S, Denys P, Krupp J, Joussain C.   +10 more
europepmc   +1 more source

The effectiveness and safety of oral medications, onabotulinumtoxinA (three doses) and transcutaneous tibial nerve stimulation as non or minimally invasive treatment for the management of neurogenic detrusor overactivity in adults: a systematic review and network meta-analysis. [PDF]

Int J Surg, 2023
Chen Y, Peng L, Zhang C, Chen J, Chen J, Shen H, Luo D.   +6 more
europepmc   +1 more source

In Patients with Neurogenic Detrusor Overactivity and Hinman's Syndrome: Would Intravesical Botox Injections Decrease the Incidence of Symptomatic Urinary Tract Infections. [PDF]

Res Rep Urol, 2021
Banakhar M, Yamani A.
europepmc   +1 more source

Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open-label, phase 3, dose-titration study. [PDF]

Neurourol Urodyn, 2021
Baka-Ostrowska M, Bolong DT, Persu C, Tøndel C, Steup A, Lademacher C, Martin N.   +6 more
europepmc   +1 more source

Comparison of the efficacy and safety of sacral root magnetic stimulation with transcutaneous posterior tibial nerve stimulation in the treatment of neurogenic detrusor overactivity: an exploratory randomized controlled trial. [PDF]

Transl Androl Urol, 2022
Zhao Y, Wang D, Zou L, Mao L, Yu Y, Zhang T, Bai B, Chen Z.   +7 more
europepmc   +1 more source

AbobotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of spinal cord injury or multiple sclerosis etiology: Pooled analysis of two phase III randomized studies (CONTENT1 and CONTENT2). [PDF]

Neurourol Urodyn, 2023
Denys P, Castaño Botero JC, Vita Nunes RL, Wachs B, Mendes Gomes C, Krivoborodov G, Tu LM, Del-Popolo G, Thompson C, Vilain C, Volteau M, Kennelly M, Dysport CONTENT program group.   +12 more
europepmc   +1 more source

Urodynamic and Anamnestic Predictors for Individual Dose Adjustment of Intravesical Oxybutynin in Neurogenic Detrusor Overactivity: Results From the UPSIDE Study. [PDF]

Neurourol Urodyn
Van Ophoven A, Banek S, Becker K, Heibel M, Hirsch A, Kieruj M, Kurze I, Lingnau A, Ludwikowski B, Luithle T, Queissert F, Rösch W, Schindler O, Stredele R, Völkl TMK, Leidl Q, Gedamke M.   +16 more
europepmc   +1 more source